29P Plasma ESR1 mutations and outcome to first-line chemotherapy with bevacizumab and paclitaxel in patients with advanced ER-positive/HER2-negative breast cancer

Autor:	Manouk K. Bos, Epie Boven, Agnes Jager, M.P.H.M. Jansen, S.W. Lam, Jwm Martens, Jean A. Helmijr, Stefan Sleijfer, Corine M. Beaufort
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty Bevacizumab business.industry HER2 negative Hematology medicine.disease chemistry.chemical_compound Breast cancer Paclitaxel chemistry Internal medicine medicine In patient First line chemotherapy business Estrogen receptor alpha medicine.drug
Zdroj:	Annals of Oncology. 32:S32-S33
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.03.043
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e576a2f12bae7713c2bbecb6224cbb42 https://doi.org/10.1016/j.annonc.2021.03.043 Zobrazit plný text záznamu